Metastases - malecare.org

On The Horizon- FDA Grants Fast Track Designation for OGX-011 in The Treatment of Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]

By Malecare|2017-10-19T10:54:28-04:00October 12th, 2009|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, Metastases, On The Horizon, Uncategorized|0 Comments

Factors Pointing to the Development of Metastatic Prostate Cancer

It is inevitable; most men with prostate cancer, who require treatment with androgen deprivation therapy (ADT), will eventually become resistance to treatment leading to the development of metastatic disease. Men who develop metastatic castrate-resistant disease have a very poor prognosis. Historically, their overall survival is estimated only to be 24 to 36 months. A study [...]

By Malecare|2017-10-19T10:54:35-04:00September 4th, 2009|Advanced Prostate Cancer, General Information, Hormone Therapy, Metastases, Research, Uncategorized, Understanding APC|0 Comments

A Telephone Workshop on Metastatic Prostate Cancer

Cancer Care is conducting a telephone workshop on Metastatic Prostate Cancer on Tuesday, September 22, 2009 from 1:30 to 2:30 eastern time. Listening in on the workshop is free. Participants in the workshop will be: Susan Slovin MD, PhD, Associate Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for the Treatment of Prostate & Urologic [...]

By Malecare|2020-02-04T10:10:57-05:00August 18th, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Metastases, Uncategorized, Understanding APC|0 Comments

Combining Radiopharmaceuticals and Bisphosphonates to Treat Bone Mets

A recent study of one man at the Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, The Netherlands combined both treatment modalities, radiopharmaceuticals and bisphosphonates, to combat bone pain caused by bone metastases. Their results were surprising. Bone-seeking radiopharmaceuticals and bisphosphonates are both an indicated treatment for men with prostate cancer when painful [...]

By Malecare|2017-10-19T10:54:41-04:00August 15th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments

Extending Survival of Prostate Cancer Survivors by Using Sodium Clodronate

In a small trial using oral sodium clodronate, a bisphosphonate like Zometa and Fosamax, it was shown to extended prostate cancer survival by 23 percent (23%). The survival benefit was seen only when the drug was used in combination with hormone therapy in men with metastatic disease. Many doctors have believed that bisphosphonates could have [...]

By Malecare|2017-10-19T10:54:42-04:00August 13th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Metastases, Research, Uncategorized, Understanding APC|0 Comments